Robert Arthur Harrington net worth and biography

Robert Harrington Biography and Net Worth

Director of Cytokinetics

Dr. Harrington has served as a member of our Board of Directors since April 2022.

Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials. A previous American Heart Association (AHA) president, Dr. Harrington remains a member of AHA’s Board of Directors. He is also an elected member of the Association of American Physicians, the Association of University Cardiologists, and the National Academy of Medicine / Institute of Medicine. In addition, he has served as a chair and member of the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Among his numerous awards and recognition, Dr. Harrington was named a Master of the American College of Cardiology in 2016, was awarded the AHA’s Clinical Research Prize in 2017, and earned the AHA Council on Clinical Cardiology (CLCD) Distinguished Achievement Award in 2022. In 2022, he was awarded the Stokes Medal, and in 2023, Honorary Fellowship in the Irish Cardiac Society. Dr. Harrington earned a B.A. in English at the College of the Holy Cross and an M.D. from Tufts University School of Medicine.

What is Robert Arthur Harrington's net worth?: The estimated net worth of Robert Arthur Harrington is at least $773,627.76 as of July 5th, 2024. Dr. Harrington owns 15,516 shares of Cytokinetics stock worth more than $773,628 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Harrington may own. Learn More about Robert Arthur Harrington's net worth.
How do I contact Robert Arthur Harrington?: The corporate mailing address for Dr. Harrington and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Robert Arthur Harrington's contact information.
Has Robert Arthur Harrington been buying or selling shares of Cytokinetics?: Robert Arthur Harrington has not been actively trading shares of Cytokinetics during the last ninety days. Most recently, Robert Arthur Harrington sold 253 shares of the business's stock in a transaction on Friday, July 5th. The shares were sold at an average price of $54.61, for a transaction totalling $13,816.33. Following the completion of the sale, the director now directly owns 15,516 shares of the company's stock, valued at $847,328.76. Learn More on Robert Arthur Harrington's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 43 times. They sold a total of 432,011 shares worth more than $27,490,574.11. The most recent insider tranaction occured on November, 18th when CEO Robert I Blum sold 5,000 shares worth more than $252,750.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 11/18/2024.

Robert Arthur Harrington Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/5/2024	Sell	253	$54.61	$13,816.33	15,516
6/3/2024	Sell	1,580	$48.64	$76,851.20	15,541

Robert Arthur Harrington Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $49.86

$49.65

$50.95

50 Day Range

MA: $53.86

$49.86

$58.62

2 Week Range

Now: $49.86

$30.68

$110.25

Volume

1,063,163 shs

Average Volume

2,057,156 shs

Market Capitalization

$5.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.